8 June 2018
We are pleased to announce that JPD is working in partnership with The Cure Parkinson’s Trust (CPT) to provide information about breaking research news to be featured on the new web portal for people with Parkinson’s (PwPs) called Parkinson’s Movement: parkinsonsmovement.com.
Parkinson’s Movement strives to strengthen the position of Parkinson's as a health priority globally: "By providing a genuine, powerful tool for driving change, we can inform and influence the agenda of the wider Parkinson’s community."
Hype versus Hope: What Does It All Mean?
One section of the site is dedicated to sifting through recent research in order to concisely capture a snapshot of the science and translate it to deliver better understanding for all. The research summaries are divided into three categories: potential new; risk factors & genetics; and mechanisms of disease. Assessing the impact of published PD-related research is done through a panel of experts, researchers and PwPs.
Providing invaluable perspective, these panel members rate papers according to their impact and relevance, so that patients can be informed how relevant the latest PD scientific research news actually is. The JPD scientific panel consists of JPD Editor-in-Chief Patrik Brundin and a number of members of the JPD Editorial Board.
Announcing the Parkinson's Webinar Series: Widening Engagement, Increasing Transparency
Communicating about research is a vital aspect of creating awareness. The site features research articles that hit the news and it particularly focuses on debunking myths, balancing over hyped headlines and ensuring the research is placed in context.
A number of published JPD papers have already been the focus of attention – including a paper linking diabetes and PD (rated as 73% impact, see here) and another paper which discusses whether the cholesterol-lowering drug Simvastatin may slow or stop Parkinson’s progression (rated as 90% impact, see here).
Soon, a new JPD research study will be under scrutiny in a new venture that is being launched as part of a brand new Quarterly Parkinson's Webinar Series, delivered by Parkinson’s Movement, JPD and CPT. By bringing the discussion of specific research topics into the open, the whole process of rating research will become even more transparent.
Date for your diary!
The inaugural webinar will take place on June 19 in London, UK (5.30 pm BST, 12.30 pm EST) and the topic for discussion will be: “Does exenatide reduce non-motor symptoms in Parkinson’s disease?”
The focus of the discussion will be a recent JPD article focusing on exenatide. The webinar will be chaired by Professor Patrik Brundin and joined by fellow panellists: Tom Foltynie from UCL in London, who led the exenatide trial; Nigel Greig and Dimitrios Kapogiannis from the NIA (National Institute of Aging); and exenatide trial participant Penny Kustow.
This webinar will be recorded and available online afterwards but will only be available for live viewing to the first 100 participants to sign up. The 100 people watching live you will also be able to submit questions for the panel during the webinar. Take part in the discussion by registering for a place!